Levalbuterol Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Levalbuterol prescription in 2026, you're not imagining things. While Levalbuterol (Xopenex, Xopenex HFA) is not on the FDA's official drug shortage list, patients across the country are encountering empty pharmacy shelves and lengthy wait times. Here's everything you need to know about the current situation.

Is Levalbuterol Officially in Shortage in 2026?

The short answer: No, not officially. The FDA Drug Shortage Database does not list Levalbuterol as a current shortage as of 2026. The American Society of Health-System Pharmacists (ASHP) also notes that most Levalbuterol inhalation solution presentations are currently available at the wholesale level.

However, "available at the wholesale level" doesn't mean it's sitting on the shelf at your local pharmacy. Individual pharmacies — especially smaller retail chains and independent stores — may have limited or no stock at any given time.

What's Causing Levalbuterol Stock Gaps in 2026?

Several overlapping factors explain why patients are encountering difficulty finding Levalbuterol:

1. The Albuterol Shortage Ripple Effect

The ongoing albuterol nebulizer solution shortage — which began in October 2022 and was severely worsened when Akorn Pharmaceuticals permanently closed its three U.S. plants in early 2023 — drove hospitals and providers to prescribe Levalbuterol as a substitute. This pushed demand well beyond what levalbuterol manufacturers were prepared to handle.

Experts warned at the time that levalbuterol production volume is far lower than albuterol's, meaning manufacturers couldn't easily scale up. While the FDA approved new albuterol manufacturers — Ritedose Pharmaceuticals in November 2025 and Amneal Pharmaceuticals in March 2026 — the demand surge on levalbuterol left a lasting impact on pharmacy inventory patterns.

2. Low Baseline Pharmacy Stock

Levalbuterol costs 5 to 10 times more than albuterol and has significantly lower prescription volume. This means most retail pharmacies carry minimal stock. When even a modest number of new prescriptions come through, that small inventory depletes rapidly.

3. Seasonal Demand Spikes

Fall and winter respiratory virus seasons (RSV, flu, COVID-19) drive significant increases in bronchodilator prescriptions. This affects all SABAs, including Levalbuterol. Pharmacy supply chains that are already thin struggle to absorb these seasonal surges.

4. Limited Number of Manufacturers

Levalbuterol requires additional manufacturing steps compared to racemic albuterol to isolate the pure R-enantiomer. Fewer generic manufacturers produce it, which means less supply redundancy. When one manufacturer experiences delays or quality issues, the entire market feels the impact.

What Formulations Are Hardest to Find?

Based on patient reports and pharmacy ordering patterns, the formulations most frequently out of stock include:

0.31 mg/3 mL nebulizer solution — the pediatric dosing strength, used most in children ages 6-11

The Xopenex HFA inhaler may be more consistently available than the nebulizer solution at retail pharmacies

Higher-dose nebulizer solutions (0.63 mg and 1.25 mg/3 mL) tend to be more available than the 0.31 mg strength

What Should Patients Do Right Now?

Here are concrete steps you can take today to make sure you don't run out:

Use medfinder: medfinder calls pharmacies near you to check which ones have your specific Levalbuterol formulation and strength in stock, then texts you the results — no hold music, no repeated explanations.

Refill early: Try to refill your prescription when you still have 7-10 days of medication remaining.

Ask about alternatives: Talk to your doctor about whether albuterol could serve as a backup. For most patients, both drugs are clinically equivalent.

Try hospital pharmacies: Hospital outpatient pharmacies tend to stock Levalbuterol more consistently than retail chains.

Consider mail order: Mail-order pharmacies can often source medications that local retail stores lack. Many insurance plans offer 90-day supplies via mail.

Looking Ahead: Will Levalbuterol Get Easier to Find?

As the albuterol shortage continues to ease in 2026 with new manufacturers coming online, some of the cross-demand on Levalbuterol should decrease. However, levalbuterol's fundamental supply chain limitations — fewer manufacturers, higher cost, lower baseline inventory — are structural challenges that won't be solved quickly.

The best protection is staying proactive. For detailed strategies, see our guide on how to find Levalbuterol in stock near you.